Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and ... Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company is also advancing its proprietary late stage photodynamic therapy (PDT) platform that holds promise as a localized cutaneous or visceral tumor treatment as well as in other potential indications. Mostra di più
| Periodo † | Var | Var % | Apert. | Max | Min | Med. Vol. Giorn. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.07 | -1.92837465565 | 3.63 | 4 | 3.23 | 506310 | 3.66149106 | CS |
| 4 | 0.83 | 30.4029304029 | 2.73 | 4 | 1.8 | 277761 | 3.19702214 | CS |
| 12 | -0.54 | -13.1707317073 | 4.1 | 5.5 | 1.8 | 237732 | 3.84687432 | CS |
| 26 | -2.99 | -45.6488549618 | 6.55 | 7.93 | 1.8 | 277471 | 4.64876549 | CS |
| 52 | -2.99 | -45.6488549618 | 6.55 | 7.93 | 1.8 | 277471 | 4.64876549 | CS |
| 156 | -2.99 | -45.6488549618 | 6.55 | 7.93 | 1.8 | 277471 | 4.64876549 | CS |
| 260 | -2.99 | -45.6488549618 | 6.55 | 7.93 | 1.8 | 277471 | 4.64876549 | CS |
| Nessuna Discussione Trovata |
| Crea Discussione |
Assistenza: support@advfn.it
Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni
Caratteristiche principali
Premium
